14c-lenvatinib mesylate

From WikiMD's free health, diet & wellness encyclopedia
Jump to navigation Jump to search

14c-lenvatinib mesylate - a radioconjugate composed of the orally bioavailable mesylate salt form of lenvatinib, a receptor tyrosine kinase (rtk) inhibitor, labeled with the radioisotope carbon c 14, with potential use for evaluating the pharmacokinetic profile of lenvatinib. Upon administration of carbon c14 lenvatinib mesylate, lenvatinib targets and binds strongly to multiple rtks, including vascular endothelial growth factor receptor 1 (vegfr1;flt1), vegfr2 (kdr), vegfr3 (flt4), fibroblast growth factor receptor 1 (fgfr1), fgfr2, fgfr3, and fgfr4, platelet derived growth factor receptor alpha (pdgfra), kit, and ret. This inhibits growth of tumor cells that overexpress these rtks. Labeling of lenvatinib with the radioactive tracer carbon c 14 permits the evaluation of lenvatinib's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (adme).

Up to date info


Latest research - 14c-lenvatinib mesylate

Clinical trials

Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 14c-lenvatinib mesylate for any updates.


14c-lenvatinib mesylate is part of WikiMD's free ^articles!

^14c-lenvatinib mesylate (article) is provided for informational purposes only. No expressed or implied warranties as to the validity of content.
WikiMD is not a substitute for professional advice. By accessing and using WikiMD you agree to the terms of use.
Templates etc. when imported from Wikipedia, are licensed under CC BY-SA 3.0. See full disclaimers.
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's physician weight loss program can HELP. Tele medicine available